325 related articles for article (PubMed ID: 11920300)
1. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.
Genton B; Betuela I; Felger I; Al-Yaman F; Anders RF; Saul A; Rare L; Baisor M; Lorry K; Brown GV; Pye D; Irving DO; Smith TA; Beck HP; Alpers MP
J Infect Dis; 2002 Mar; 185(6):820-7. PubMed ID: 11920300
[TBL] [Abstract][Full Text] [Related]
2. Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity.
Flück C; Schöpflin S; Smith T; Genton B; Alpers MP; Beck HP; Felger I
Infect Genet Evol; 2007 Jan; 7(1):44-51. PubMed ID: 16647307
[TBL] [Abstract][Full Text] [Related]
3. Strain-specific humoral response to a polymorphic malaria vaccine.
Flück C; Smith T; Beck HP; Irion A; Betuela I; Alpers MP; Anders R; Saul A; Genton B; Felger I
Infect Immun; 2004 Nov; 72(11):6300-5. PubMed ID: 15501757
[TBL] [Abstract][Full Text] [Related]
4. Plasmodium falciparum: distribution of msp2 genotypes among symptomatic and asymptomatic individuals from the Wosera region of Papua New Guinea.
Cortés A; Mellombo M; Benet A; Lorry K; Rare L; Reeder JC
Exp Parasitol; 2004; 106(1-2):22-9. PubMed ID: 15013785
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G
Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875
[TBL] [Abstract][Full Text] [Related]
6. Plasmodium falciparum: malaria morbidity is associated with specific merozoite surface antigen 2 genotypes.
Engelbrecht F; Felger I; Genton B; Alpers M; Beck HP
Exp Parasitol; 1995 Aug; 81(1):90-6. PubMed ID: 7628572
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children.
Genton B; Al-Yaman F; Betuela I; Anders RF; Saul A; Baea K; Mellombo M; Taraika J; Brown GV; Pye D; Irving DO; Felger I; Beck HP; Smith TA; Alpers MP
Vaccine; 2003 Dec; 22(1):30-41. PubMed ID: 14604568
[TBL] [Abstract][Full Text] [Related]
8. [NANP]19-5.1. A malaria vaccine field trial in Nigerian children.
Reber-Liske R; Salako LA; Matile H; Sowunmi A; Stürchler D
Trop Geogr Med; 1995; 47(2):61-3. PubMed ID: 8592764
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
10. Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea.
Marfurt J; Müeller I; Sie A; Maku P; Goroti M; Reeder JC; Beck HP; Genton B
Am J Trop Med Hyg; 2007 Nov; 77(5):947-54. PubMed ID: 17984359
[TBL] [Abstract][Full Text] [Related]
11. Effect of vitamin A supplementation on morbidity due to Plasmodium falciparum in young children in Papua New Guinea: a randomised trial.
Shankar AH; Genton B; Semba RD; Baisor M; Paino J; Tamja S; Adiguma T; Wu L; Rare L; Tielsch JM; Alpers MP; West KP
Lancet; 1999 Jul; 354(9174):203-9. PubMed ID: 10421302
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria.
al-Yaman F; Genton B; Anders R; Taraika J; Ginny M; Mellor S; Alpers MP
Parasite Immunol; 1995 Sep; 17(9):493-501. PubMed ID: 8552419
[TBL] [Abstract][Full Text] [Related]
13. Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys.
Hisaeda H; Saul A; Reece JJ; Kennedy MC; Long CA; Miller LH; Stowers AW
J Infect Dis; 2002 Mar; 185(5):657-64. PubMed ID: 11865423
[TBL] [Abstract][Full Text] [Related]
14. Rapid selection of dhfr mutant allele in Plasmodium falciparum isolates after the introduction of sulfadoxine/pyrimethamine in combination with 4-aminoquinolines in Papua New Guinea.
Mita T; Kaneko A; Hwaihwanje I; Tsukahara T; Takahashi N; Osawa H; Tanabe K; Kobayakawa T; Björkman A
Infect Genet Evol; 2006 Nov; 6(6):447-52. PubMed ID: 16600696
[TBL] [Abstract][Full Text] [Related]
15. Vaccines for preventing malaria.
Graves P; Gelband H
Cochrane Database Syst Rev; 2003; (1):CD000129. PubMed ID: 12535387
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of three Pichia pastoris-expressed Plasmodium falciparum merozoite proteins as a combination vaccine against infection with blood-stage parasites.
Zhang D; Pan W
Infect Immun; 2005 Oct; 73(10):6530-6. PubMed ID: 16177327
[TBL] [Abstract][Full Text] [Related]
17. Heritability and segregation analysis of immune responses to specific malaria antigens in Papua New Guinea.
Stirnadel HA; Beck HP; Alpers MP; Smith TA
Genet Epidemiol; 1999; 17(1):16-34. PubMed ID: 10323182
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of SPf 66 P. falciparum vaccine in children.
Indian Pediatr; 1995 Feb; 32(2):261-2. PubMed ID: 8635799
[No Abstract] [Full Text] [Related]
19. Restricted T-cell epitope diversity in the circumsporozoite protein from Plasmodium falciparum populations prevalent in Iran.
Zakeri S; Avazalipoor M; Mehrizi AA; Djadid ND; Snounou G
Am J Trop Med Hyg; 2007 Jun; 76(6):1046-51. PubMed ID: 17556609
[TBL] [Abstract][Full Text] [Related]
20. The Plasmodium sporozoite survives RTS,S vaccination.
Snounou G; Grüner AC; Müller-Graf CD; Mazier D; Rénia L
Trends Parasitol; 2005 Oct; 21(10):456-61. PubMed ID: 16109504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
